Humalog Mix: Uses, Dosage & Side Effects
Insulin lispro protamine / insulin lispro — Biphasic insulin analogue for diabetes management
Quick Facts About Humalog Mix
Key Takeaways About Humalog Mix
- Dual insulin action: Humalog Mix 50 combines rapid-acting and intermediate-acting insulin in a single injection, providing both mealtime and background glucose control
- Inject before meals: Administer within 15 minutes before or immediately after a meal due to its rapid onset of action
- Hypoglycemia is the main risk: Low blood sugar is the most common side effect — always carry glucose tablets or a sugary drink
- Never share pens: Insulin pens must never be shared between patients, even if the needle is changed, due to risk of infection
- Storage matters: Store unopened in fridge (2–8°C); once in use, keep at room temperature (below 30°C) for up to 28 days
What Is Humalog Mix and What Is It Used For?
Humalog Mix 50 is a biphasic insulin analogue used to treat diabetes mellitus. It contains 50% rapid-acting insulin lispro and 50% intermediate-acting insulin lispro protamine suspension, providing both mealtime and basal insulin coverage in a single subcutaneous injection.
Humalog Mix 50 belongs to a class of medications known as biphasic insulin analogues. Insulin lispro is a genetically engineered form of human insulin that has been modified to provide a faster onset of action compared to regular human insulin. The rapid-acting component (insulin lispro) starts working within approximately 15 minutes of injection, while the intermediate-acting component (insulin lispro protamine suspension) provides a sustained glucose-lowering effect lasting up to 18–24 hours.
This medication is prescribed for patients with type 1 diabetes mellitus, where the pancreas produces little or no insulin, and type 2 diabetes mellitus, where the body does not use insulin effectively and may eventually produce insufficient amounts. Humalog Mix can be used in adults, adolescents, and children aged 2 years and older who require insulin for maintaining adequate glycemic control.
The "50/50" formulation indicates that half of the insulin in the mixture is rapid-acting and the other half is intermediate-acting. This higher proportion of rapid-acting insulin (compared to Humalog Mix 25, which contains only 25% rapid-acting insulin) makes Humalog Mix 50 particularly suitable for patients who require greater postprandial (after-meal) glucose control. The specific formulation chosen depends on individual blood glucose patterns, dietary habits, and the clinical judgment of the treating physician.
Insulin therapy, including biphasic formulations like Humalog Mix, is a cornerstone of diabetes management as recommended by the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the World Health Organization (WHO). Effective insulin therapy reduces the risk of long-term complications including diabetic retinopathy, nephropathy, neuropathy, and cardiovascular disease.
Insulin lispro has two amino acids (proline and lysine at positions B28 and B29) reversed compared to human insulin. This small structural change reduces the tendency of insulin molecules to form hexamers, allowing more rapid absorption from the injection site. The result is a faster onset of action (15 minutes vs. 30–60 minutes for regular human insulin) and a shorter duration of peak activity, which more closely mimics the body's natural mealtime insulin response.
What Should You Know Before Taking Humalog Mix?
Before starting Humalog Mix, inform your doctor about all medical conditions, other medications, and any previous allergic reactions to insulin. Never use Humalog Mix when your blood sugar is low (hypoglycemia) or if you are allergic to insulin lispro or any of the excipients.
Contraindications
Humalog Mix must not be used in the following situations:
- Hypoglycemia: Never inject insulin when your blood glucose is already low. This can cause a dangerous further drop in blood sugar that may lead to loss of consciousness, seizures, or death
- Allergy to insulin lispro: Do not use if you have a known hypersensitivity to insulin lispro or any of the other ingredients in the formulation (including protamine sulfate, metacresol, phenol, glycerol, dibasic sodium phosphate, or zinc oxide)
- Intravenous administration: Humalog Mix suspensions must never be administered intravenously. They are designed exclusively for subcutaneous injection
- Use in insulin pumps: Biphasic insulin formulations including Humalog Mix must not be used in continuous subcutaneous insulin infusion pumps
Warnings and Precautions
Several important precautions should be observed when using Humalog Mix:
- Blood glucose monitoring: Regular self-monitoring of blood glucose is essential. Target ranges should be individualized in consultation with your healthcare provider. Inadequate monitoring increases the risk of both hypoglycemia and hyperglycemia
- Injection technique: Rotate injection sites within the same body region (abdomen, thigh, upper arm, or buttock) to reduce the risk of lipodystrophy (changes in fat tissue under the skin). The absorption rate may vary between different body regions
- Dose adjustments: Insulin requirements may change during illness (particularly infections with fever), emotional stress, changes in physical activity levels, or alterations in diet. Your doctor may need to adjust your dose during these periods
- Hypoglycemia awareness: Some patients may lose the ability to recognize early warning symptoms of hypoglycemia (hypoglycemia unawareness), especially those with longstanding diabetes, those using beta-blockers, or those with frequent hypoglycemic episodes
- Renal and hepatic impairment: Insulin requirements may be reduced in patients with kidney or liver disease. Closer monitoring and more frequent dose adjustments may be necessary
- Hypokalemia: Insulin therapy can cause a shift of potassium from the extracellular to the intracellular compartment, potentially leading to hypokalemia. This is particularly relevant in patients taking potassium-lowering medications or those with conditions predisposing to hypokalemia
- Thiazolidinedione combination: Using insulin with thiazolidinediones (e.g., pioglitazone) may increase the risk of heart failure due to fluid retention. Monitor for signs and symptoms of heart failure
Insulin pens, cartridges, and needles must never be shared between patients, even if the needle is changed. Sharing poses a serious risk of transmitting blood-borne infections including hepatitis B, hepatitis C, and HIV.
Pregnancy and Breastfeeding
Good glycemic control is critically important during pregnancy to reduce the risk of complications for both mother and baby, including pre-eclampsia, macrosomia, birth injuries, and neonatal hypoglycemia. Insulin lispro can be used during pregnancy when clinically indicated.
Insulin requirements typically decrease during the first trimester and increase during the second and third trimesters. After delivery, insulin requirements usually return rapidly to pre-pregnancy levels. Close monitoring of blood glucose with frequent dose adjustments is essential throughout pregnancy and the postpartum period.
Insulin lispro is compatible with breastfeeding. Patients with diabetes who are breastfeeding may require adjustments in insulin dose, meal plan, or both. Insulin is a large protein molecule that is broken down in the infant's gastrointestinal tract and is not absorbed intact, so it does not pose a risk to the nursing infant.
How Does Humalog Mix Interact with Other Drugs?
Several medications can affect blood glucose levels and may require dose adjustments when used with Humalog Mix. Drugs that increase insulin sensitivity or lower blood glucose can increase the risk of hypoglycemia, while others can raise blood sugar and reduce insulin effectiveness.
Drug interactions with insulin are clinically significant because they can lead to either hypoglycemia (dangerously low blood sugar) or hyperglycemia (elevated blood sugar). It is essential to inform your healthcare provider about all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you are taking. The following table summarizes the most important interactions.
Major Interactions
These medications significantly affect blood glucose levels and may require careful dose adjustments or enhanced monitoring when used with Humalog Mix:
| Drug / Drug Class | Mechanism | Clinical Action |
|---|---|---|
| Sulfonylureas (glimepiride, glipizide, glyburide) | Stimulate endogenous insulin secretion; additive glucose-lowering effect | Monitor blood glucose closely; dose reduction of one or both agents may be needed |
| GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) | Enhance insulin secretion and slow gastric emptying; additive glucose-lowering | Reduce insulin dose when initiating GLP-1 therapy; monitor closely |
| ACE inhibitors (enalapril, lisinopril, ramipril) | May increase insulin sensitivity | Monitor blood glucose; dose adjustment may be required |
| MAO inhibitors | May enhance insulin-mediated glucose uptake | Enhanced blood glucose monitoring; dose reduction may be needed |
| Salicylates (high-dose aspirin) | Increase peripheral glucose utilization and reduce hepatic glucose production | Monitor blood glucose when starting or stopping high-dose salicylate therapy |
| Fibrates (fenofibrate, gemfibrozil) | May improve insulin sensitivity | Monitor blood glucose; insulin dose adjustment may be needed |
Drugs That May Reduce Insulin Effect
| Drug / Drug Class | Mechanism | Clinical Action |
|---|---|---|
| Corticosteroids (prednisolone, dexamethasone) | Increase hepatic glucose production and reduce insulin sensitivity | Significant insulin dose increase usually required; monitor glucose frequently |
| Thiazide diuretics (hydrochlorothiazide) | Reduce insulin secretion and increase insulin resistance | Monitor blood glucose; adjust insulin dose as needed |
| Oral contraceptives | May decrease insulin sensitivity | Monitor blood glucose when starting or stopping; dose adjustment may be needed |
| Thyroid hormones (levothyroxine) | Increase hepatic glucose output and glucose absorption | Monitor blood glucose during thyroid dose changes |
| Sympathomimetics (salbutamol, terbutaline) | Stimulate glycogenolysis and gluconeogenesis via beta-2 adrenergic pathways | Monitor blood glucose; insulin dose increase may be needed with systemic use |
| Atypical antipsychotics (olanzapine, clozapine) | Cause insulin resistance and impair glucose metabolism | Monitor blood glucose regularly; insulin dose may need increasing |
Beta-blockers (e.g., propranolol, atenolol, metoprolol) deserve special mention. They can mask the typical adrenergic warning signs of hypoglycemia such as tremor, palpitations, and tachycardia. Non-selective beta-blockers may also delay blood glucose recovery. Patients using beta-blockers with insulin should be counseled about recognizing alternative hypoglycemia symptoms such as sweating, hunger, difficulty concentrating, and confusion. Cardioselective beta-blockers (e.g., bisoprolol, metoprolol) are generally preferred in patients with diabetes.
Alcohol: Alcohol consumption can both increase and decrease blood glucose levels. Moderate alcohol intake may enhance the glucose-lowering effect of insulin and increase the risk of delayed hypoglycemia, particularly on an empty stomach. Patients should be aware of these effects and monitor blood glucose more frequently when consuming alcohol.
What Is the Correct Dosage of Humalog Mix?
Humalog Mix dosing is highly individualized based on blood glucose levels, metabolic needs, dietary habits, and physical activity. There is no single "correct" dose — your healthcare provider will determine and adjust your specific dose through regular monitoring.
Insulin dosing must be individualized for each patient. The total daily insulin requirement for most patients with diabetes ranges from 0.5 to 1.0 IU/kg/day, although this can vary widely depending on the type and duration of diabetes, degree of insulin resistance, physical activity level, and dietary patterns. The prescribing physician will determine the initial dose and adjust it based on blood glucose monitoring results.
Adults
Type 2 Diabetes — Adults
Starting dose: Typically 0.2–0.4 IU/kg/day, divided across meals. Patients transitioning from other insulin regimens may start at an equivalent total daily dose.
Administration: Inject subcutaneously within 15 minutes before a meal, or immediately after a meal. Humalog Mix 50 is usually given twice daily (before breakfast and before the evening meal).
Dose titration: Adjust dose by 1–2 units every 3–7 days based on self-monitored blood glucose readings. Target fasting blood glucose is typically 4.4–7.2 mmol/L (80–130 mg/dL) and postprandial glucose below 10.0 mmol/L (180 mg/dL) according to ADA guidelines.
Type 1 Diabetes — Adults
Total daily dose: Typically 0.5–1.0 IU/kg/day. Humalog Mix may be used as part of a multiple-injection regimen or as a simplified regimen depending on individual needs.
Administration: Usually twice or three times daily before main meals. The dose distribution depends on individual meal patterns and glucose responses.
Note: Most patients with type 1 diabetes achieve better control with a basal-bolus regimen (separate long-acting and rapid-acting insulins). Premixed insulin may be considered for patients who prefer fewer injections or have difficulty managing a more complex regimen.
Children and Adolescents
Children Aged 2 Years and Older
Total daily dose: Typically 0.5–1.0 IU/kg/day in prepubertal children, increasing to 1.0–2.0 IU/kg/day during puberty due to increased insulin resistance from growth hormones.
Administration: Same as adults — inject within 15 minutes before meals. Doses should be calculated and supervised by a pediatric endocrinologist or diabetes specialist.
Important: Humalog Mix is not recommended for children under 2 years of age due to lack of clinical data in this population.
Elderly Patients
Patients Over 65 Years
Dosing considerations: Elderly patients may have reduced renal clearance and altered insulin sensitivity. Starting doses should be conservative, with gradual titration. Less stringent glycemic targets (e.g., HbA1c below 8.0% or 64 mmol/mol) may be appropriate for frail elderly patients or those with multiple comorbidities.
Monitoring: More frequent blood glucose monitoring is recommended. The risk of hypoglycemia is higher in elderly patients and the consequences can be more severe (falls, fractures, cardiovascular events).
Missed Dose
If you miss a dose of Humalog Mix:
- Check your blood glucose level immediately
- If blood glucose is high and it is not too close to your next scheduled dose, inject the missed dose
- Never inject a double dose to compensate for a missed injection
- If you are unsure, contact your healthcare provider or diabetes educator
- Monitor blood glucose more frequently for the next 24 hours until levels stabilize
Overdose
An insulin overdose causes hypoglycemia, which ranges from mild (symptoms of sweating, tremor, hunger, confusion) to severe (loss of consciousness, seizures, coma). The severity depends on the degree of overdose relative to the patient's usual dose and food intake.
Mild hypoglycemia: Treat immediately by consuming 15–20 grams of fast-acting carbohydrate (e.g., glucose tablets, fruit juice, regular soda). Recheck blood glucose after 15 minutes and repeat if necessary. Follow with a complex carbohydrate snack.
Severe hypoglycemia (unconsciousness, seizures, inability to swallow): Do not attempt to give food or drink by mouth. Administer glucagon injection (1 mg intramuscularly or subcutaneously) if available. Call emergency services immediately. Place the patient in the recovery position. Intravenous glucose (20% or 50% dextrose) will be administered by medical professionals.
What Are the Side Effects of Humalog Mix?
The most common side effect of Humalog Mix is hypoglycemia (low blood sugar). Other side effects include injection site reactions, lipodystrophy, allergic reactions, and edema. Most side effects are manageable with proper technique and monitoring.
Like all insulins, Humalog Mix can cause side effects, although not everybody experiences them. The most clinically significant adverse effect is hypoglycemia, which can occur if the insulin dose is too high relative to food intake and physical activity. The following frequency-based classification is derived from clinical trial data and post-marketing surveillance as reported in the European Medicines Agency (EMA) Summary of Product Characteristics and FDA prescribing information.
Very Common
- Hypoglycemia — Low blood sugar causing symptoms such as sweating, tremor, hunger, dizziness, palpitations, confusion, visual disturbances, and in severe cases loss of consciousness or seizures
Common
- Injection site reactions — Redness, swelling, itching, or pain at the injection site. Usually mild and transient
- Lipodystrophy — Thickening (lipohypertrophy) or thinning (lipoatrophy) of fat tissue at injection sites. Reduced by rotating injection sites
- Peripheral edema — Swelling of hands, ankles, or feet, particularly when initiating insulin therapy or during intensive dose escalation
Uncommon
- Local allergic reactions — More extensive redness, swelling, or itching at the injection site that may spread beyond the immediate area
- Visual disturbances — Temporary blurred vision due to changes in lens refraction with rapid glucose normalization. Usually resolves within days to weeks
- Cutaneous amyloidosis — Skin lumps at injection sites that can affect insulin absorption if injected into affected areas
Rare
- Systemic allergic reactions — Generalized skin rash, angioedema, bronchospasm, hypotension, or anaphylaxis. Requires immediate medical attention
- Insulin antibody formation — Development of antibodies that may alter insulin effectiveness, potentially requiring dose adjustment or a change in insulin preparation
- Painful peripheral neuropathy — Rarely, rapid improvement in glycemic control can temporarily worsen diabetic neuropathy symptoms (treatment-induced neuropathy of diabetes)
Seek immediate medical attention for signs of severe hypoglycemia (confusion, loss of consciousness, seizures), signs of a severe allergic reaction (widespread rash, difficulty breathing, rapid heartbeat, swelling of face or throat), or persistent and worsening injection site reactions. Report any unexpected or bothersome side effects to your doctor, pharmacist, or national pharmacovigilance authority.
How Should You Store Humalog Mix?
Store unopened Humalog Mix in a refrigerator at 2–8°C. Once in use, keep at room temperature (below 30°C) for up to 28 days. Do not freeze insulin. Never use insulin that looks abnormal after gentle resuspension.
Proper storage of insulin is essential to maintain its effectiveness and safety. Incorrect storage can lead to loss of potency and unpredictable blood glucose control. Follow these guidelines carefully:
- Unopened (not in use): Store in a refrigerator at 2–8°C (36–46°F). Keep in the original carton to protect from light. Do not place directly against the cooling element of the refrigerator as freezing will destroy the insulin
- In-use: Once a cartridge or pen is in use, it can be stored at room temperature (below 30°C / 86°F) for up to 28 days. Do not refrigerate in-use pens as cold insulin injections can be more painful
- Do not freeze: Frozen insulin must be discarded. Once insulin has been frozen, it is permanently damaged and will not work properly even after thawing
- Protect from heat and light: Do not expose to direct sunlight, extreme heat, or leave in a hot car. Temperatures above 30°C degrade insulin
- Expiry date: Do not use after the expiry date printed on the label, even if stored correctly
- Before each use: Gently roll the pen or cartridge between your palms 10 times, then invert it 10 times to resuspend the insulin. The suspension should appear uniformly milky white after mixing. Do not use if it remains clear, contains clumps, or has white particles sticking to the bottom or wall of the cartridge
When traveling, keep insulin in a cool bag or insulated case (not in direct contact with ice packs). Never place insulin in checked luggage on flights, as the cargo hold can reach freezing temperatures. Carry a prescription letter from your doctor when traveling internationally, and always bring more insulin than you think you will need in case of travel delays.
What Does Humalog Mix Contain?
Humalog Mix 50 contains insulin lispro as the active substance, combined with protamine sulfate to create the intermediate-acting component. Excipients include metacresol and phenol (preservatives), glycerol, dibasic sodium phosphate, zinc oxide, and water for injection.
Each milliliter of Humalog Mix 50 suspension for injection contains:
- Active substance: Insulin lispro 100 IU (equivalent to 3.5 mg). Of this, 50% is in the form of insulin lispro protamine suspension (intermediate-acting) and 50% is insulin lispro solution (rapid-acting)
- Protamine sulfate: Complexed with insulin lispro to slow absorption, creating the intermediate-acting component
- Metacresol: Preservative
- Phenol: Preservative
- Glycerol: Tonicity modifier
- Dibasic sodium phosphate (7H2O): Buffer
- Zinc oxide: Stabilizer (adjusted to provide up to 25 mcg zinc per 100 IU insulin lispro)
- Water for injection: Vehicle
- Hydrochloric acid and/or sodium hydroxide: pH adjustment (pH 7.0–7.8)
Insulin lispro is produced by recombinant DNA technology in Escherichia coli (E. coli). The manufacturing process involves fermentation, purification, and quality testing in accordance with European Pharmacopoeia and FDA regulatory standards. The final product is free from bacterial contaminants and endotoxins.
Allergy information: Patients with a known allergy to protamine may be at increased risk of allergic reactions to Humalog Mix due to the protamine sulfate content. Protamine allergy is more common in patients who have previously received protamine-containing medications (e.g., NPH insulin, protamine sulfate for heparin reversal). If you have a known protamine allergy, inform your healthcare provider before starting Humalog Mix.
Frequently Asked Questions About Humalog Mix
Humalog Mix 25 contains 25% rapid-acting insulin lispro and 75% intermediate-acting insulin lispro protamine, while Humalog Mix 50 contains 50% of each component. The Mix 50 formulation provides more prandial (mealtime) insulin coverage, making it particularly useful for patients who experience significant postprandial blood glucose spikes. Your doctor will select the formulation based on your individual blood glucose patterns, meal composition, and overall treatment goals. Some patients may use Mix 25 at one meal and Mix 50 at another, depending on their needs.
Yes, insulin lispro can be used during pregnancy when clinically needed. Maintaining tight glycemic control is essential throughout pregnancy to reduce the risk of maternal and fetal complications. Insulin requirements typically decrease in the first trimester and increase during the second and third trimesters. Your healthcare team will monitor your blood glucose closely and adjust your insulin dose frequently. After delivery, insulin requirements usually return rapidly to pre-pregnancy levels.
The rapid-acting component of Humalog Mix 50 begins working within approximately 15 minutes of subcutaneous injection. Peak glucose-lowering activity occurs between 1 and 4 hours after injection. The intermediate-acting protamine component extends the overall duration of action to approximately 18–24 hours. This is why Humalog Mix should be injected within 15 minutes before a meal or immediately after — the rapid onset is designed to match the blood glucose rise that occurs with food intake.
No. Humalog Mix is a pre-mixed biphasic insulin formulation and should not be mixed with any other insulin preparations. The product is designed to deliver a precise ratio of rapid-acting and intermediate-acting insulin. Mixing with other insulins could alter the pharmacokinetic profile and result in unpredictable blood glucose control. If your treatment plan requires different insulin types, administer them as separate injections at different sites.
If you experience symptoms of hypoglycemia (sweating, tremor, hunger, dizziness, palpitations, confusion, blurred vision), act immediately. Consume 15–20 grams of fast-acting carbohydrate such as glucose tablets, fruit juice, or regular soda. Wait 15 minutes and recheck your blood glucose. If still low, repeat the carbohydrate intake. Once blood glucose normalizes, eat a small snack containing complex carbohydrates and protein to prevent recurrence. If you experience severe hypoglycemia (loss of consciousness, seizures, inability to eat or drink), someone should administer glucagon and call emergency services immediately.
Before injection, gently roll the pen between your palms 10 times, then invert it 10 times to resuspend the insulin uniformly. Select your injection site — the abdomen, thigh, upper arm, or buttock are all suitable. Rotate sites within the same region to prevent lipodystrophy. Clean the skin with an alcohol swab if recommended by your healthcare provider. Attach a new needle, dial the correct dose, and insert the needle at a 90-degree angle (or 45 degrees if you are very lean). Press the injection button and hold the needle in place for at least 10 seconds to ensure complete delivery. Remove the needle and dispose of it safely in a sharps container.
References
- European Medicines Agency (EMA). Humalog — Summary of Product Characteristics. Updated 2024. Available at: EMA EPAR Humalog.
- U.S. Food and Drug Administration (FDA). Humalog Prescribing Information. Eli Lilly and Company. Updated 2024.
- American Diabetes Association (ADA). Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S1–S352.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Insulin preparations including insulin lispro.
- Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589–2625.
- Rosenstock J, Bajaj HS, Engel SS, et al. Premixed insulin analogs: a comparison of Humalog Mix formulations with human premixed insulins. Diabetes Care. 2008;31(Suppl 2):S131–S136.
- British National Formulary (BNF). Insulin lispro. National Institute for Health and Care Excellence (NICE). Updated 2025.
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th edition, 2021.
- Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology. 2017;13(7):385–399.
Editorial Team
Medical Content
iMedic Medical Editorial Team
Specialists in endocrinology, clinical pharmacology, and internal medicine. All content is based on current international guidelines (ADA, EASD, EMA, FDA, WHO) and peer-reviewed research.
Medical Review
iMedic Medical Review Board
Independent panel of board-certified physicians who review all content according to GRADE evidence framework and international medical standards.
Evidence Standard: All medical claims in this article are based on Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) or official regulatory documents (EMA SmPC, FDA label). No commercial funding was received. This content is independent of pharmaceutical industry influence.